RSRC2 (arginine and serine rich coiled-coil 2) is a multifunctional tumor suppressor gene and RNA-binding protein located on chromosome 12. Functionally, RSRC2 acts as a tumor suppressor by inhibiting cell proliferation and regulating alternative splicing of cancer-related genes 1. The protein contains RNA-binding capacity and associates with splicing machinery and centrosomal proteins 2. Mechanistically, RSRC2 operates through multiple pathways: it transcriptionally inhibits SCIN expression to suppress cell adhesion, migration, and invasion 3, and it interacts with the long non-coding RNA C1QTNF1-AS1 to direct proper mitotic gene splicing and maintain centrosome integrity through recruitment of centrosomal scaffold proteins 2. Additionally, RSRC2 is subject to alternative splicing regulation by TRA2A, which modulates its isoform composition and protein expression levels 4. Clinically, RSRC2 expression inversely correlates with cancer aggressiveness across multiple malignancies. In esophageal squamous cell carcinoma, low RSRC2 expression correlates with increased invasion, lymph node metastasis, and poor prognosis 1. In triple-negative breast cancer, reduced RSRC2 expression associates with paclitaxel resistance and worse survival 43. RSRC2 represents a potential biomarker and therapeutic target for cancer treatment decisions.